Cara Therapeutics | CARA - Operating Expenses


Cara Therapeutics reported $7.05M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Cassava Sciences USD 11.17M 2.38M Mar/2026
Chugai Pharma JPY 180.73B 17.74B Jun/2026
Cipla INR 62.31B 3.04B Jun/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.19M 96K Mar/2026
CSL USD 5.7B 2.82B Dec/2025
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
J&J USD 17.83B 388M Jun/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Pacira USD 180.54M 7.79M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
RedHill Biopharma USD 5.51M 1.08M Jun/2024
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025